ASTER DM Healthcare's (ASTERDM) Q3 consolidated EBITDA (adj. for ESOP) grew 23% YoY to Rs1.94bn, in line with our estimate. ASTERDM India's EBITDA has increased sharply over the last 2 years (29% CAGR over FY22-24). Our FY25-27E EBITDA estimate stands unchanged. We estimate 23% EBITDA CAGR over FY25-27E aided by scale-up in margins, healthy ARPOB and bed additions. ASTER DM's board has recently approved merger with Quality care (QCIL) that makes them third largest healthcare chain by revenue and bed capacity in India. The combined entity is trading at ~20x EV/EBITDA on FY27E (adj. for minority stake and rental) which is discount to some of peers and unwarranted given higher growth profile, backing of marquee PE investors like Blackstone and combined entity scale of operations.